Joseph Fralin Woody

Director Joseph Fralin Woody purchased 5.2K shares of RCEL at $4.00; stock now down 42.1% from 52-week high amid ongoing losses.

Joseph Fralin Woody, a director, purchased 5,200 shares at $4.00 on 2026-06-09, increasing his holdings from 102.8K to 108.0K shares. The transaction occurs as RCEL trades -42.1% from its 52-week high of $7.12 and -5.7% over the prior 30 days. AVITA Medical remains unprofitable with net income of $-10.6M in the latest quarter despite annual revenue growth of +11.4%; the company's market cap is $126.8M. At the same ticker, Woody's prior three measurable buys showed mixed outcomes (2 of 3 well-timed at the 90-day mark), though his cross-ticker track record reflects an average 90-day return of -1.8% with a 33.33% win rate across 8 prior buys. The purchase into a depressed valuation in a loss-making, small-cap biomedical device company presents a data point for investors monitoring director conviction relative to near-term price momentum and fundamental trajectory.

RCEL Director Woody buys 10,000 shares in 2 transactions at $4.20 and $4.18 (avg $4.19)—stock near 52-week lows.

Director Joseph Fralin Woody purchased 10,000 shares across 2 separate transactions on 2026-06-09 at blended average price of $4.19, increasing his holdings from 92.8K to 102.8K shares (+10.8%). The purchase prices ($4.20 and $4.18) align closely with the current price of $4.12, positioning the transaction near the lower end of the 52-week range ($3.22–$7.12) and well below the 52-week high by 42.1%. AVITA Medical reported $19.3M in revenue for the latest quarter with a net loss of $-10.6M and negative full-year profitability, while achieving 11.4% annual revenue growth. The modest transaction size relative to his existing 92.8K-share position and the unprofitable fundamental backdrop limit the significance of this purchase as a broad conviction indicator.

Director Joseph Fralin Woody buys 10,000 shares at RCEL for $40,949.00 amid -41.3% decline from 52-week high

Director Joseph Fralin Woody purchased 10,000 shares totaling $40,949.00 across 2 transactions on 2026-06-03 at prices of $4.10 and $4.09, raising his holdings from 82.8K shares to 92.8K shares (+12.1%). The purchase occurs in a context of significant stock weakness: the current price of $4.18 is -41.3% from the 52-week high of $7.12, and the stock has declined -5.4% over the past 30 days and -12.0% over 90 days. The company remains unprofitable with net income of $-10.6M against quarterly revenue of $19.3M, though annual revenue growth stands at +11.4%. The director's accumulation while the stock trades well below its recent peak suggests conviction, though the underlying profitability headwind limits the signal strength.

Director Joseph Fralin Woody purchases 20,000 shares (20.0K shares) across 4 transactions for $84,936.50 at average $4.25

Joseph Fralin Woody, a Director, made 4 separate purchases totaling 20,000 shares for $84,936.50 at a blended average price of $4.25 on June 1-2, 2026. His post-transaction holding of 20,000 shares represents a full acquisition from zero prior position. The stock currently trades at $4.16, down 2.8% over 30 days and 13.0% over 90 days, and sits -41.6% from its 52-week high of $7.12. Against this context, the purchase prices of $4.18–$4.34 are modest premiums to the current market, but the company faces material profitability challenges: it reported a quarterly revenue of $19,251,000.00 with a net loss of $-10,611,000.00, and was unprofitable over its most recent full fiscal year. The transaction's significance is tempered by the lack of prior holdings, the absence of pattern or magnitude to establish conviction, and the company's ongoing operational losses despite 11.4% annual revenue growth.